Concepedia

Heidi H. Gillenwater

HH

25

Publications

2.9K

Citations

19

H-Index

1999

Active since

Affiliations

University of North Carolina at Chapel Hill(Current)

The University of Texas MD Anderson Cancer Center

City Of Hope National Medical Center

University of Virginia

UPMC Hillman Cancer Center

Heidi H. Gillenwater is an author at University of North Carolina at Chapel Hill specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1999–2021

25

Publications

25

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Gary M. Strauss, James E. Herndon, Michael A. Maddaus et al. · Journal of Clinical Oncology · 2008 · 975 citations · Full text

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 834 citations · Full text

, , +8

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Mark A. Socinski, Silvia Novello, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2008 · 320 citations · Full text

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie et al. · Blood · 2021 · 116 citations · Full text

, , +20

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer

Thomas A. Hensing, Nasser H. Hanna, Heidi H. Gillenwater et al. · Anti-Cancer Drugs · 2006 · 69 citations

Rows per page

1–5 of 25